Active

Giura Pharma

Switched

BE0692655422

Rechtspersoon Private limited company 1 establishment

Heidelaan 25, 2580 Putte Activiteiten van holdings

Active for

8 year, 5 months

Financials

Financial year 2025

Gross margin

€ 122,490

▲ 12% vs 2024

Profit

Growing

€ 81,021

▲ 12% vs 2024

Debts

Low

€ 535,385

▲ 79% vs 2024

Giura Pharma from Putte, company number BE0692655422, closed financial year 2025 with a result of € 81,021 after tax. For that financial year Giura Pharma recorded a gross margin of € 122,490 and equity of € 461,457. Compared with financial year 2024, the result moved from € 72,134 to € 81,021. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 28, 2026.

What happened at Giura Pharma?

What happened at Giura Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • New annual accounts for financial year 2025: profit of € 81,021 (▲ 12% vs 2024). Source: NBB ↗
  • New establishment in Putte. KBO
  • Start of the company according to the CBE. KBO

In short

From € 54,761 profit in 2021 to € 81,021 profit in 2025.

Paid € 172,474 in corporate taxes since 2021.

Best year ever: 2025, with € 81,021 profit.

A new publication or filing at Giura Pharma? We notify you, reason included.

Follow Giura Pharma

Need more data?

History

Every financial year, as far back as the National Bank goes.

Buffer

How long does the company survive without income?

Credit limit

Indicative credit limit, computed from the real figures.

Alerts

New annual account: profit halved. New
Gazette: capital increase of 250k. New

News about who you follow, reason included.

Databakkes Pro · first month free

Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.

Management

Caroline Caenepeel
Giura Pharma

Behind Giura Pharma is Caroline Caenepeel. It owns 50% of Relst Pharma and 50% of Apotrem itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Caroline Caenepeel

Director

Also active at: Relst Pharma, APOTREM

Establishments

Establishment units

Physical locations of this company

Registered office

Heidelaan 25

2580 Putte

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

Details

Company number
0692.655.422
VAT number
BE 0692.655.422
Registered office
Heidelaan 25, 2580 Putte
Names & denominations
Giura Pharma
Enterprise type
Rechtspersoon
Legal form
Private limited company
Legal situation
Normale toestand
Start date
19 March 2018
Peppol
Active · Active since 27 Mar 2026
Activities · NACE

Activiteiten van holdings

Holdings

Frequently asked questions

What is the enterprise number of Giura Pharma?
The enterprise number of Giura Pharma is BE0692655422.
What is the address of Giura Pharma?
The registered office of Giura Pharma is located at Heidelaan 25, 2580 Putte.
When was Giura Pharma founded?
Giura Pharma was founded on 19 March 2018.
What is the main activity of Giura Pharma?
The main activity of Giura Pharma is "Activiteiten van holdings" (NACE code 64210).
Does Giura Pharma have a website?
No website is currently known for Giura Pharma.
How much profit did Giura Pharma make in 2025?
Giura Pharma posted a profit after taxes of € 81,021 in financial year 2025.
What is the revenue of Giura Pharma?
As a small company, Giura Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 122,490.
Where can I find the annual accounts of Giura Pharma?
Giura Pharma files its annual accounts with the Central Balance Sheet Office of the National Bank of Belgium. The key figures for recent financial years are available for free on this page.
Who are the directors of Giura Pharma?
According to the 2025 annual accounts, the directors of Giura Pharma are: Caroline Caenepeel.
Who owns Giura Pharma?
Behind Giura Pharma is Caroline Caenepeel. It owns 50% of Relst Pharma and 50% of Apotrem itself.